Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebicapone multiple rising dose study in healthy volunteers
NCT02772627Phase 1Completed
- Sponsor
- BIAL
- Start
- Sep 2001
- Primary completion
- Dec 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nebicapone in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma concentration at Day 8, Time of maximum observed concentration at Day 8 and 6 more. Started Sep 2001; status: completed.
02
Drugs
nebicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02772627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772627.